Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Biosynthesis of DHEA and estrogens.
Figuras y tablas -
Figure 1

Biosynthesis of DHEA and estrogens.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study flow diagram.
Figuras y tablas -
Figure 2

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 4

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores).
Figuras y tablas -
Figure 5

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects.
Figuras y tablas -
Figure 6

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores).
Figuras y tablas -
Figure 7

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis).
Figuras y tablas -
Figure 8

Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 1 QoL/wellbeing (end scores).
Figuras y tablas -
Analysis 1.1

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 1 QoL/wellbeing (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 2 Sensitivity analysis QoL/wellbeing (end scores).
Figuras y tablas -
Analysis 1.2

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 2 Sensitivity analysis QoL/wellbeing (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 3 QoL (subgrouped on Low Libido/HSDD).
Figuras y tablas -
Analysis 1.3

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 3 QoL (subgrouped on Low Libido/HSDD).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 4 QoL (subgrouped on treatment duration).
Figuras y tablas -
Analysis 1.4

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 4 QoL (subgrouped on treatment duration).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 5 QoL/General Wellbeing (change scores).
Figuras y tablas -
Analysis 1.5

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 5 QoL/General Wellbeing (change scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 6 Side‐effects.
Figuras y tablas -
Analysis 1.6

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 6 Side‐effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 7 Acne subgrouped on study duration.
Figuras y tablas -
Analysis 1.7

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 7 Acne subgrouped on study duration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 8 Menopausal symptoms (continuous).
Figuras y tablas -
Analysis 1.8

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 8 Menopausal symptoms (continuous).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 9 Menopausal symptoms (dichotomous).
Figuras y tablas -
Analysis 1.9

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 9 Menopausal symptoms (dichotomous).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 10 Sexual Function (end scores).
Figuras y tablas -
Analysis 1.10

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 10 Sexual Function (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 11 Sexual function (end scores) (sensitivity analysis).
Figuras y tablas -
Analysis 1.11

Comparison 1 DHEA versus control (placebo or no treatment), Outcome 11 Sexual function (end scores) (sensitivity analysis).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 1 QoL/wellbeing (change scores).
Figuras y tablas -
Analysis 2.1

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 1 QoL/wellbeing (change scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 2 Side‐effects: acne.
Figuras y tablas -
Analysis 2.2

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 2 Side‐effects: acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 4 Sexual Function (end scores).
Figuras y tablas -
Analysis 2.4

Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 4 Sexual Function (end scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 DHEA versus HT, Outcome 1 QoL/General Wellbeing.
Figuras y tablas -
Analysis 3.1

Comparison 3 DHEA versus HT, Outcome 1 QoL/General Wellbeing.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 DHEA versus HT, Outcome 3 Menopausal symptoms (continuous).
Figuras y tablas -
Analysis 3.3

Comparison 3 DHEA versus HT, Outcome 3 Menopausal symptoms (continuous).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 DHEA versus HT, Outcome 4 Sexual Function.
Figuras y tablas -
Analysis 3.4

Comparison 3 DHEA versus HT, Outcome 4 Sexual Function.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 1 Acne.
Figuras y tablas -
Analysis 4.1

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 1 Acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 2 Hair loss.
Figuras y tablas -
Analysis 4.2

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 2 Hair loss.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 3 Headache.
Figuras y tablas -
Analysis 4.3

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 3 Headache.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 4 Nausea.
Figuras y tablas -
Analysis 4.4

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 4 Nausea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 5 Leg cramps.
Figuras y tablas -
Analysis 4.5

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 5 Leg cramps.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 6 Breast Tenderness.
Figuras y tablas -
Analysis 4.6

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 6 Breast Tenderness.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 7 Bloating.
Figuras y tablas -
Analysis 4.7

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 7 Bloating.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 8 Weight gain.
Figuras y tablas -
Analysis 4.8

Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 8 Weight gain.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 1 Tiredness.
Figuras y tablas -
Analysis 5.1

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 1 Tiredness.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 2 Hot flushes and palpitations.
Figuras y tablas -
Analysis 5.2

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 2 Hot flushes and palpitations.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 3 Night sweats.
Figuras y tablas -
Analysis 5.3

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 3 Night sweats.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 4 Vaginal Dryness.
Figuras y tablas -
Analysis 5.4

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 4 Vaginal Dryness.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 5 Pruritis Vulvae.
Figuras y tablas -
Analysis 5.5

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 5 Pruritis Vulvae.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 6 Urethral Syndrome.
Figuras y tablas -
Analysis 5.6

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 6 Urethral Syndrome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 7 Depression.
Figuras y tablas -
Analysis 5.7

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 7 Depression.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 8 Loss of libido.
Figuras y tablas -
Analysis 5.8

Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 8 Loss of libido.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase

DHEA compared to control (placebo or no treatment)

Population: women in the peri‐ or postmenopausal phase
Settings:
Intervention: DHEA
Comparison: control (placebo or no treatment)

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

control (placebo or no treatment)

DHEA

QoL, wellbeing (end scores) (sensitivity analysis)
different scales for quality of life (QoL)

The mean QoL, wellbeing in the intervention groups was
0.16 standard mean differences higher
(‐0.03 lower to 0.34 higher)

287 (132 from parallel and 155 from crossover)
(8 studies)

⊕⊕⊕⊝
moderate1

SMD 0.16 (‐0.03 to 0.34)

Side effects (androgenic overall combined with acne)
number of events

25 per 1000

87 per 1000
(33 to 210)

OR 3.77
(1.36 to 10.47)

250
(5 studies)

⊕⊕⊕⊝
moderate1

Side effects ‐ androgenic side effects
number of events

44 per 1000

234 per 1000
(60 to 595)

OR 6.57
(1.37 to 31.59)

92
(1 study)

⊕⊕⊝⊝
low1,2

Only 1 study for this outcome

Side effects ‐ acne
number of events

13 per 1000

29 per 1000
(7 to 107)

OR 2.26
(0.56 to 9.02)

158
(4 studies)

⊕⊕⊕⊝
moderate1

*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded for imprecision due to wide confidence intervals
2 Downgraded due to no other studies available for comparison of effects

Figuras y tablas -
Summary of findings for the main comparison. DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase
Ir a la tabla de la revisión
Summary of findings 2. Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase

Oral DHEA versus control subgrouped by routes of administration for women in the peri‐ or postmenopausal phase***

Population: Women in the peri‐ or postmenopausal phase
Settings:
Intervention: DHEA versus placebo (via different routes of administration)

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

DHEA

QoL, wellbeing (change scores) ‐ oral administration

The mean QoL, wellbeing in the intervention groups was
0.05 standard deviations lower
(0.53 lower to 0.43 higher)

66
(1 study)

⊕⊝⊝⊝
very low1

SMD ‐0.05 (‐0.53 to 0.43)

QoL, wellbeing (change scores) ‐ intravaginal application

The mean QoL/wellbeing in the intervention groups was
1.23 standard deviations higher
(0.82 to 1.65 higher)

107
(1 study)

⊕⊝⊝⊝
very low1,2,3

SMD 1.23 (0.82 to 1.65)

Side effects: acne ‐ skin application

0 per 1000

126per 1000**
(52 to 798)

OR 2.74
(0.1 to 74.87)

22
(1 study)

⊕⊝⊝⊝
very low1,2

Side effects: acne ‐ oral administration

15 per 1000

32 per 1000
(7 to 133)

OR 2.16
(0.47 to 9.96)

136
(3 studies)

⊕⊝⊝⊝
very low4,5

*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio

** As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

***There were no studies that compared different routes of treatment within the study. We have separated studies based on their route of administration and compared the results from these studies with each other.

1 Downgraded due to no other studies available for comparison of effects
2 Downgraded due to limited information on randomisation, allocation and blinding
3 Included subjects with complaints of vaginal dryness, itching, dyspareunia
4Results are controversial (2/3 studies favour placebo, whereas 1 favours DHEA)
5 Downgraded due to large CIs

Figuras y tablas -
Summary of findings 2. Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase
Ir a la tabla de la revisión
Summary of findings 3. DHEA versus HT for women in the peri‐ or postmenopausal phase

DHEA versus HT for women in the peri‐ or postmenopausal phase

Population: Women in the peri‐ or postmenopausal phase
Settings:
Intervention: DHEA versus HT

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

HT

DHEA

QoL, general wellbeing DHEA versus ET

The mean QoL in the intervention groups was

1.63 higher

(2.25 lower to 5.52 higher)

17
(1 study)

⊕⊝⊝⊝
very low1

QoL, general wellbeing
DHEA versus ET + P

No studies available

QoL, general wellbeing DHEA versus tibolone

No studies available

Acne
DHEA versus ET

0 per 1000

472 per 1000
(45 to 943)

OR 17
(0.9 to 320.37)

50
(1 study)

⊕⊝⊝⊝
very low1

Acne

DHEA versus tibolone

0 per 1000

472 per 1000**
(45 to 944)

OR 17
(0.9 to 320.37)

50
(1 study)

⊕⊝⊝⊝
very low1,2

Acne

DHEA versus ET + P

No studies available

*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

**As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded due to no other studies available for comparison of effects
2 Study was not blinded ‐ may have influenced the outcomes

Figuras y tablas -
Summary of findings 3. DHEA versus HT for women in the peri‐ or postmenopausal phase
Ir a la tabla de la revisión
Comparison 1. DHEA versus control (placebo or no treatment)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 QoL/wellbeing (end scores) Show forest plot

9

Std. Mean Difference (Fixed, 95% CI)

‐0.04 [‐0.20, 0.13]

2 Sensitivity analysis QoL/wellbeing (end scores) Show forest plot

8

Std. Mean Difference (Fixed, 95% CI)

0.16 [‐0.03, 0.34]

3 QoL (subgrouped on Low Libido/HSDD) Show forest plot

9

Std. Mean Difference (Fixed, 95% CI)

Subtotals only

3.1 Low Libido/HSDD

2

Std. Mean Difference (Fixed, 95% CI)

0.10 [‐0.26, 0.46]

3.2 Libido normal/unknown

7

Std. Mean Difference (Fixed, 95% CI)

‐0.08 [‐0.27, 0.11]

4 QoL (subgrouped on treatment duration) Show forest plot

9

Std. Mean Difference (Fixed, 95% CI)

‐0.04 [‐0.20, 0.13]

4.1 <6 weeks

3

Std. Mean Difference (Fixed, 95% CI)

0.23 [‐0.11, 0.57]

4.2 6 to 26 weeks

3

Std. Mean Difference (Fixed, 95% CI)

0.13 [‐0.13, 0.39]

4.3 >26 weeks

3

Std. Mean Difference (Fixed, 95% CI)

‐0.46 [‐0.75, ‐0.16]

5 QoL/General Wellbeing (change scores) Show forest plot

2

Std. Mean Difference (IV, Fixed, 95% CI)

Totals not selected

6 Side‐effects Show forest plot

5

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Androgenic side‐effects

1

92

Odds Ratio (M‐H, Fixed, 95% CI)

6.57 [1.37, 31.59]

6.2 Acne

4

158

Odds Ratio (M‐H, Fixed, 95% CI)

2.26 [0.56, 9.02]

6.3 Hirsutism

1

89

Odds Ratio (M‐H, Fixed, 95% CI)

4.89 [0.23, 104.76]

7 Acne subgrouped on study duration Show forest plot

4

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 < 6 weeks

1

27

Odds Ratio (M‐H, Fixed, 95% CI)

0.29 [0.01, 7.70]

7.2 >6 weeks to 26 weeks

1

22

Odds Ratio (M‐H, Fixed, 95% CI)

2.74 [0.10, 74.87]

7.3 >26 weeks

2

109

Odds Ratio (M‐H, Fixed, 95% CI)

5.25 [0.58, 47.36]

8 Menopausal symptoms (continuous) Show forest plot

2

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

8.1 Endscores

1

17

Std. Mean Difference (IV, Fixed, 95% CI)

0.35 [‐0.70, 1.40]

8.2 Change scores

1

66

Std. Mean Difference (IV, Fixed, 95% CI)

0.07 [‐0.42, 0.55]

9 Menopausal symptoms (dichotomous) Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

9.1 Flushes

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Hot flushes and palpitations

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.3 Insomnia

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.4 Night sweats

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.5 Depression

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.6 Loss of libido

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.7 Vaginal dryness

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.8 Pruritis vulvae

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.9 Urethral syndrome

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.10 Tiredness

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Sexual Function (end scores) Show forest plot

6

Std. Mean Difference (Fixed, 95% CI)

0.19 [‐0.01, 0.40]

11 Sexual function (end scores) (sensitivity analysis) Show forest plot

5

Std. Mean Difference (Fixed, 95% CI)

0.31 [0.07, 0.55]
Figuras y tablas -
Comparison 1. DHEA versus control (placebo or no treatment)
Ir a la tabla de la revisión
Comparison 2. Oral DHEA versus control subgrouped by route of administration

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 QoL/wellbeing (change scores) Show forest plot

2

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Oral administration

1

66

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.05 [‐0.53, 0.43]

1.2 Intravaginal application

1

107

Std. Mean Difference (IV, Fixed, 95% CI)

1.23 [0.82, 1.65]

2 Side‐effects: acne Show forest plot

4

158

Odds Ratio (M‐H, Fixed, 95% CI)

2.26 [0.56, 9.02]

2.1 Skin application

1

22

Odds Ratio (M‐H, Fixed, 95% CI)

2.74 [0.10, 74.87]

2.2 Oral administration

3

136

Odds Ratio (M‐H, Fixed, 95% CI)

2.16 [0.47, 9.96]

4 Sexual Function (end scores) Show forest plot

6

Std. Mean Difference (Fixed, 95% CI)

0.19 [‐0.01, 0.40]

4.1 Oral administration

5

Std. Mean Difference (Fixed, 95% CI)

0.11 [‐0.13, 0.35]

4.2 Intravaginal application

1

Std. Mean Difference (Fixed, 95% CI)

0.42 [0.03, 0.81]
Figuras y tablas -
Comparison 2. Oral DHEA versus control subgrouped by route of administration
Ir a la tabla de la revisión
Comparison 3. DHEA versus HT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 QoL/General Wellbeing Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

1.1 ET

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Combined

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Tibolone

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Menopausal symptoms (continuous) Show forest plot

2

Std. Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 ET

1

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Combined

1

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.3 Tibolone

1

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Sexual Function Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

4.1 ET/ET+P

2

41

Mean Difference (IV, Fixed, 95% CI)

1.26 [‐0.21, 2.73]

4.2 Tibolone

1

24

Mean Difference (IV, Fixed, 95% CI)

4.60 [0.92, 8.28]
Figuras y tablas -
Comparison 3. DHEA versus HT
Ir a la tabla de la revisión
Comparison 4. DHEA versus HT (side effects) (dichotomous)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Acne Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

17.0 [0.90, 320.37]

1.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

17.0 [0.90, 320.37]

2 Hair loss Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

10.67 [0.54, 209.64]

2.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

10.67 [0.54, 209.64]

3 Headache Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.03 [0.00, 0.53]

3.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.18 [0.01, 4.04]

4 Nausea Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.22 [0.04, 1.21]

4.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.13, 7.72]

5 Leg cramps Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Breast Tenderness Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.07 [0.00, 1.40]

6.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 8.25]

7 Bloating Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.09 [0.00, 1.84]

7.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.18 [0.01, 4.04]

8 Weight gain Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.09 [0.00, 1.84]

8.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.18 [0.01, 4.04]
Figuras y tablas -
Comparison 4. DHEA versus HT (side effects) (dichotomous)
Ir a la tabla de la revisión
Comparison 5. DHEA versus HT (menopausal symptoms) (dichotomous)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tiredness Show forest plot

1

100

Odds Ratio (M‐H, Fixed, 95% CI)

1.26 [0.49, 3.26]

1.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.26 [0.33, 4.84]

1.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.26 [0.33, 4.84]

2 Hot flushes and palpitations Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.40 [0.28, 7.00]

2.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.40 [0.28, 7.00]

3 Night sweats Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.18, 5.51]

3.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.72 [0.14, 3.59]

4 Vaginal Dryness Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.06, 16.93]

4.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

3.12 [0.12, 80.39]

5 Pruritis Vulvae Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.06, 16.93]

5.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

3.12 [0.12, 80.39]

6 Urethral Syndrome Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.48 [0.04, 5.65]

6.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.06, 16.93]

7 Depression Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 8.25]

7.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Loss of libido Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 ET

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 8.25]

8.2 Tibolone

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 5. DHEA versus HT (menopausal symptoms) (dichotomous)
Ir a la tabla de la revisión